title: Leprosy Diagnostic Test Development As a Prerequisite Towards Elimination: Requirements from the User's Perspective.
authors: Novartis Foundation, Novartis Campus, Basel, Switzerland.
authors: Edith
authors: E
authors: Roset Bahmanyar
authors: School of Medicine, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
authors: William Cairns
authors: WC
authors: Smith
authors: Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States of America.
authors: Patrick
authors: P
authors: Brennan
authors: PATH, Seattle, Washington, United States of America.
authors: Ray
authors: R
authors: Cummings
authors: Infectious Disease Research Institute, Seattle, Washington, United States of America.
authors: Malcolm
authors: M
authors: Duthie
authors: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
authors: Jan Hendrik
authors: JH
authors: Richardus
authors: American Leprosy Missions, Greenville, South Carolina, United States of America.
authors: Paul
authors: P
authors: Saunderson
authors: American Leprosy Missions, Yangon, Myanmar.
authors: Tin
authors: T
authors: Shwe
authors: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America.
authors: Steven
authors: S
authors: Rosen
authors: Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
authors: Annemieke
authors: A
authors: Geluk
mesh_terms: D003955:Diagnostic Tests, Routine / Q000379:methods*; D060740:Disease Eradication / Q000379:methods; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D014943:Global Health; D006801:Humans; D007918:Leprosy / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity